Clinical trial
A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants…
NCT02795767 · Hoffmann-La Roche, Industry · Completed
Key facts
| NCT number | NCT02795767 |
|---|---|
| Title | A Study of Emicizumab Administered Subcutaneously (SC) in Pediatric Participants With Hemophilia A and Factor VIII (FVIII) Inhibitors |
| Official title | A Multicenter, Open-Label, Phase III Clinical Trial to Evaluate the Efficacy, Safety, and Pharmacokinetics of Subcutaneous Administration of Emicizumab in Hemophilia A Pediatric Patients With Inhibitors |
| Acronym | HAVEN 2 |
| Lead sponsor | Hoffmann-La Roche, Industry |
| Collaborators | Chugai Pharmaceutical Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Hemophilia A |
| Intervention type | Drug |
| Interventions | Emicizumab |
| Enrollment | 88 |
| Start date | Jul 22, 2016 |
| Primary completion | Apr 30, 2018 |
| Completion | Nov 11, 2020 |
| First posted | Jun 10, 2016 |
| Last update posted | Jun 2, 2021 |
| Countries | Costa Rica, France, Germany, Italy, Japan, South Africa, Spain, Turkey (Türkiye), United Kingdom, United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: